Compare Stocks → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:BNOEFNASDAQ:KMPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNOEFBionomics$0.00-43.3%$0.00$0.00▼$0.06$4.45M1.86140,299 shs22,900 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNOEFBionomics0.00%0.00%0.00%0.00%-72.13%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNOEFBionomicsN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNOEFBionomicsN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNOEFBionomicsN/AN/AN/AN/AN/AN/AKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNOEFBionomicsN/AN/A0.00∞N/AN/AN/AN/AN/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNOEFBionomicsN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNOEFBionomicsN/AN/AN/AKMPHZevra Therapeutics0.1410.1010.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNOEFBionomicsN/AKMPHZevra Therapeutics19.39%Insider OwnershipCompanyInsider OwnershipBNOEFBionomicsN/AKMPHZevra Therapeutics1.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBNOEFBionomicsN/A1.31 billionN/ANot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableBNOEF, CAU, and KMPH HeadlinesSourceHeadlineZevra Therapeutics Shares Fall After FDA Extends Arimoclomol Reviewmarketwatch.com - March 4 at 10:23 AMBrisbane, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 20 at 6:37 PMChristchurch, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - February 17 at 7:36 PMGreater Bendigo, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - January 11 at 6:36 PMBuy Rating Affirmed for Zevra Therapeutics Amid Positive Regulatory Developments and Strong Market Positioningmarkets.businessinsider.com - January 9 at 11:59 PMZevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type Cmarkets.businessinsider.com - January 8 at 9:34 AMWellington, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - January 6 at 3:29 PMZevra seeks FDA nod for rare disease therapy arimoclomolmsn.com - December 27 at 3:28 PMZevra Therapeutics Refiles Arimoclomol Application With FDAmarketwatch.com - December 27 at 10:28 AMQueenstown, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 23 at 12:45 PMMelbourne, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 11 at 6:42 PMOroquieta City, Philippines - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 11 at 6:42 PMTehran, Iran - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - December 1 at 7:04 PMZevra Therapeutics: Promising Growth Avenues and Potential Approvals Bolster Buy Ratingmarkets.businessinsider.com - November 9 at 3:27 AMPhnom Penh, Cambodia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - October 26 at 8:36 PMNowra, Australia - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - August 26 at 4:01 PMTemuka, New Zealand - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - August 26 at 4:01 PMZevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47Mseekingalpha.com - August 14 at 4:32 PMManama, Bahrain - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 30 at 3:12 PMKanayannur, India - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 29 at 2:44 AMMonte-Carlo, Monaco - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 29 at 2:44 AMGeneva, Switzerland - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 27 at 9:51 AMBellevue, United States - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 27 at 6:18 AMNairobi, Kenya - Weather Forecasts | Maps | News - Yahoo Weatheryahoo.com - July 25 at 11:01 AMTop HeadlinesPVH Stock Gets 25% Discount: Is Now the Time to Buy?April 2, 2024 11:25 AMView PVH Stock Gets 25% Discount: Is Now the Time to Buy?4 Golden Crosses With Double-Digit Upside AheadApril 9, 2024 11:35 AMView 4 Golden Crosses With Double-Digit Upside AheadMcCormick & Company Stock Isn’t Cheap, But It Is UndervaluedMarch 26, 2024 10:28 AMView McCormick & Company Stock Isn’t Cheap, But It Is UndervaluedKeurig Dr Pepper Reaffirms Its Guidance, Time to Buy? April 1, 2024 6:15 AMView Keurig Dr Pepper Reaffirms Its Guidance, Time to Buy? NVIDIA Enters Correction: Worry or Opportunity?April 11, 2024 7:15 AMView NVIDIA Enters Correction: Worry or Opportunity?All Headlines Company DescriptionsBionomicsOTCMKTS:BNOEFBionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.